Concurrent use of gallium nitrate with other potentially nephrotoxic drugs (e.g., aminoglycosides, amphotericin B) may increase the risk for developing severe renal insufficiency in patients with cancer-related hypercalcemia. If use of a potentially nephrotoxic drug is indicated during gallium nitrate therapy, gallium nitrate administration should be discontinued and it is recommended that hydration be continued for several days after administration of the potentially nephrotoxic drug.
Serum creatinine and urine output should be closely monitored during and subsequent to this period.
Gallium nitrate therapy should be discontinued if the serum creatinine levels exceeds 2.5 mg/dL.